PATENT COOPERATION TREATY

PCT

REC'D	Î	1	JUL	2006
-------	---	---	-----	------

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABH ITY (Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

FOR FURTHER ACTION See Form PCT/IPEA/416			
PU0418-PCT	International filing date (day/mor	nth/year) Priority date (day/month/year)	
International application No.		02-04-2004	
PCT/SE2005/000467	31-03-2005	02 01 200	
International Patent Classification (IPC) o	r national classification and if C		
See Supplemental Box			
Applicant			
GE HEALTCARE BIO-SCIE	NCES AB et al		
	liminary examination report estal	blished by this International Preliminary Examining	
1. This report is the international pro Authority under Article 35 and to	ransmitted to the applicant according	ng to Article 36.	
2. This REPORT consists of a total		ing this cover sheet.	
3. This report is also accompanied by			
		a total of sheets, as follows:	
a (sent to the applican	t and to the International Bureau)	gs which have been amended and are the basis of this report	
sheets of the	description, claims and/or drawing scontaining rectifications authorized	gs which have been allicited and are a section 607 of the led by this Authority (see Rule 70.16 and Section 607 of the	
A dministrati	ve Instructions).		
sheets which	n supersede earlier sheets, but which disclosure in the international appli	this Authority considers contain an amendment that goes ication as filed, as indicated in item 4 of Box No. I and the	
Supplement	al Box.		
b. (sent to the Internat	ional Bureau only) a total of (indic	cate type and number of electronic carrier(s))	
	containing a sec	quence listing and/or tables related thereto, in electronic	
form only, as indica	ted in the Supplemental Box Relat	ting to Sequence Listing (see Section 802 of the	
Administrative Instr			
4. This report contains indications	of the report		
J	Box No. II Priority Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability		
		rd to noverty, inventive step and industrial approximation	
	of unity of invention	to the standard of the standar	
Box No. V Reaso	oned statement under Article 35(2) cability; citations and explanations	with regard to novelty, inventive step or industrial supporting such statement	
	in documents cited		
Box No. VII Certain detects in the international application			
Box No. VIII Gera			
Date of submission of the demand	Date	of completion of this report	
05-10-2005		03-07-2006	
Name and mailing address of the IPEA	,515	norized officer	
Patent- och registreringsverke	et		
Box 5055 S-102 42 STOCKHOLM	Je	ns Waltin/Els	
Faccimile No. +46, 8, 667, 72, 88		phone No. +46 8 782 25 00	

International application No.

PCT/SE2005/000467

Supplemental Box

In case the space in any of the preceding boxes is not sufficient.

Continuation of: Cover sheet

International patent classification (IPC)

B01D 15/10 (2006.01)

B01D 15/32 (2006.01)

B01D 15/36 (2006.01)

B01D 15/38 (2006.01)

CO7K 1/16 (2006.01)

International application No.

PCT/SE2005/000467

Box	No. I	Basis of the report
1.	With re	egard to the language, this report is based on:
		the international application in the language in which it was filed
		a translation of the international application into, which is the language of a translation furnished for the purposes of:
		international search (Rules 12.3(a) and 23.1(b))
		publication of the international application (Rule 12.4(a))
		international preliminary examination (Rules 55.2(a) and/or 55.3(a))
2.	furnish	regard to the elements of the international application, this report is based on (replacement sheets which have been thed to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed re not annexed to this report):
	\boxtimes	the international application as originally filed/furnished
		the description: as originally filed/furnished
		pages
		pages* received by this Authority on pages* received by this Authority on
	П	the claims:
	ш	pages as originally filed/furnished
		pages* as amended (together with any statement) under Article 19
		pages* received by this Authority on received by this Authority on
		puges
		the drawings: as originally filed/furnished
		pages as originally mediumshed pages* received by this Authority on
		pages* received by this Authority on
		a sequence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing.
3.	\Box	The amendments have resulted in the cancellation of:
J.		
		the description, pages
		the claims, Nos.
ļ		the drawings, sheets/figs
		the sequence listing (specify):
		any table(s) related to the sequence listing (specify):
4.		This report has been established as if (some of) the amendments annexed to this report and listed below had not be made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (R 70.2(c)).
1		the description, pages
		the claims, Nos.
		the drawings, sheets/figs
		the sequence listing (specify):
		any table(s) related to the sequence listing (specify):
*	If ite	em 4 applies, some or all of those sheets may be marked "superseded."

International application No.

PCT/SE2005/000467

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Claims Claims	5-7, 12-28 1-4, 8-11	YES NO
Inventive step (IS)	Claims Claims	5-7, 12-14 1-4, 8-11, 15-28	YES NO
Industrial applicability (IA)	Claims Claims	1-28	YES NO

2. Citations and explanations (Rule 70.7)

Cited prior art:

We refer to the following document, cited in the International Search Report:

D1: US 3 869 436 A

D1 relates to the fractionating of plasma proteins by ion-exchange chromatography. The method comprises:

- precipitating the globulins in the plasma with poly(ethylene glycol) (PEG),
- centrifuging out all of the precipitate from the remaining solution,
- dissolving the precipitate in sodium acetate-acetic acid,
- adsorbing the globulins from the dissolved precipitate on a cation-exchanger,
- precipitating the eluate with PEG,
- dissolving the precipitate in phosphate buffer, and
- adsorbing the globulins from the dissolved precipitate on an anion-exchanger.

Novelty:

The method according to claims 1-4, 8 and 10-11 lacks novelty in view of D1.

The method according to claims 5-6 and 12-14 includes an affinity chromatography step and the method according to claim 7 comprises three steps. The process disclosed in D1, on the other hand, comprises two ion-exchange steps.

The method according to claims 5-7 and 12-14 is thus novel in view of D1.

. . . / . . .

International application No.

PCT/SE2005/000467

Supplemental Box

In case the space in any of the preceding boxes is not sufficient. Continuation of: Box $\,\,V\,$

In the International search report, D1 was not considered relevant regarding novelty or inventive step with respect to claim 9. However, this opinion has been reassessed.

According to claim 9, the polyether is present in at least two steps. It appears from D1 (col. 3, line 7 - col. 4, line 32) that PEG is present in both the cation exchange step and in the anion exchange step. Thus, claim 9 lacks novelty in view of D1 as well.

Inventive step:

It is not considered obvious to a person skilled in the art to modify the process disclosed in D1 so as to arrive at the invention claimed in claims 5-7 or 12-14. Said claims thus present an inventive step.

The features of claims 15-17, regarding the design of the ion-exchange matrix, are known per se. They are considered to be merely some of several straightforward possibilities from which the skilled person would select, in accordance with circumstances, without the exercise of inventive skill, in order to solve the problem posed. Therefore, the invention according to claims 15-17 is considered to lack an inventive step.

The invention according to the independent claims 20 and 25 relates to a method for isolating an antibody compound from a liquid, comprising contacting the liquid, in the presence of a non-ionic polyether, with an ion-exchange chromatography matrix.

The method according to claim 20 differs from the subject matter of D1 in that the conductivity is specified to equivalent to 200 mM NaAc. NaAc is mentioned in D1 but the conductivity is not specified. However, this difference is not considered inventive. Thus, claim 20 and the dependent claims 21-24 lack an inventive step.

.../...

International application No.

PCT/SE2005/000467

Supplemental Box

In case the space in any of the preceding boxes is not sufficient. Continuation of: Box V

In independent claim 25, the design of the ion-exchange matrix is specified. For the same reasons as set out above, in connection with claims 15-17, the subject matter of claims 25-27 is considered to lack an inventive step.

Claims 18-19 and 28 relate to kits with separate compartments intended for antibody isolation. Such kits are well-known to a person skilled in the art and this solution has already been applied for the same purpose in similar contexts. Therefore, the subject matter of claims 18-19 and 28 is not considered inventive.

Industrial applicability:

The claimed invention is considered to be industrially applicable.

International application No.

PCT/SE2005/000467

Box No. VII	Certain defects in	the international	annlication
Box No. VII	Certain defects in	tne international	application

Box No. VII Certain detects in the international application			
The following defects in the form or contents of the international application have been noted:			
In claims 7-9, it seems that the words "according to any one of the preceding steps" should be replaced by "according to any one of the preceding claims".			